[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341692-105":59,"doc-detail-341692-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-approach-for-developing-a-blood-based-screening-panel-for-lung-cancer-based-on-clonal-hematopoietic-mutations-research-article","An approach for developing a blood-based screening panel for lung cancer based on clonal hematopoietic mutations - research article","","Early detection can significantly reduce mortality from lung cancer. The study presents an approach to develop a blood-based screening panel using clonal hematopoietic mutations as predictive biomarkers. Sequencing from lung cancer samples identified 98 potentially pathogenic mutations in tumor-infiltrating immune cells. These predictors were used to train a logistic regression machine-learning model, validated across 18 cohorts with 94.12% sensitivity and 85.96% specificity, suggesting an accurate screening panel is feasible.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-approach-for-developing-a-blood-based-screening-panel-for-lung-cancer-based-on-clonal-hematopoietic-mutations-research-article/341692/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-approach-for-developing-a-blood-based-screening-panel-for-lung-cancer-based-on-clonal-hematopoietic-mutations-research-article/341692.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the proposed approach?","Question",{"text":112,"@type":113},"To develop a blood-based lung cancer screening panel using clonal hematopoietic mutations as predictive biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the predictive mutations selected?",{"text":117,"@type":113},"Ninety-eight potentially pathogenic clonal hematopoietic mutations were identified using sequencing data from lung cancer samples.",{"name":119,"@type":110,"acceptedAnswer":120},"How well did the logistic regression model perform?",{"text":121,"@type":113},"It classified lung cancer and non-cancer blood samples with 94.12% sensitivity and 85.96% specificity across multiple cohorts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341692,1791096485,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","PLOS ONE  \nOPEN ACCESS  \nCitation: Anandakrishnan R, Shahidi R, Dai A, Antony V, Zyvoloski IJ (2024) An approach for developing a blood-based screening panel for lung cancer based on clonal hematopoietic mutations. PLoS ONE 19(8): e0307232 . [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1371/journal.pone](10.1371/journal.pone).0307232  \nEditor: Francesco Bertolini, European Institute of Oncology, ITALY  \nReceived: May 1, 2024  \nAccepted: July 1, 2024  \nPublished: August 22, 2024  \nPeer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here:  \n[https://doi.org/10.1371/journal.pone.0307232](https://doi.org/10.1371/journal.pone.0307232)  \n[Copyright:](Copyright:) © [2024 Anandakrishnan](2024 Anandakrishnan) et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData Availability Statement: The datasets used in the current study are available in the Genomic Data Commons Data Portal ([https://portal.gdc.cancer](https://portal.gdc.cancer). gov/) and the Sequencing Read Archive ([https://](https://)  \nRESEARCH ARTICLE  \nAn approach for developing a blood-based screening panel for lung cancer based onclonal hematopoietic mutations  \nRamuAnandakrishnan1,2 *, Ryan Shahidi1, Andrew Dai1, Veneeth Antony1, Ian  \nJ. Zyvoloski3  \n1 Edward Via College of Osteopathic Medicine, Biomedical Sciences, Blacksburg, Virginia, United States of America, 2 Maryland-Virginia College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia, United States of America, 3 University of Maryland, Baltimore, Maryland, United States of America  \n* [ramu@vt.edu](ramu@vt.edu)  \nAbstract  \nEarly detection can significantly reduce mortality due to lung cancer. Presented here is an approach for developing a blood-based screening panel based on clonal hematopoietic mutations. Animal model studies suggest that clonal hematopoietic mutations in tumor infiltrating immune cells can modulate cancer progression, representing potential predictive biomarkers. The goal of this study was to determine if the clonal expansion of these mutations in blood samples could predict the occurrence of lung cancer. A set of 98 potentially pathogenic clonal hematopoietic mutations in tumor infiltrating immune cells were identified using sequencing data from lung cancer samples. These mutations were used as predictors to develop a logistic regression machine learning model. The model was tested on sequencing data from a separate set of 578 lung cancer and 545 non-cancer samples from 18 different cohorts. The logistic regression model correctly classified lung cancer and non-cancer blood samples with 94 . 12% sensitivity (95% Confidence Interval: 92.20–96.04%) and 85.96% specificity (95% Confidence Interval: 82 .98–88.95%) . Our results suggest that it may be possible to develop an accurate blood-based lung cancer screening panel using this approach. Unlike most other “liquid biopsies” currently under development, the approach presented here is based on standard sequencing protocols and uses a relatively small number of rationally selected mutations as predictors.  \nIntroduction  \nCancer is a leading cause of death in the US, second only to heart disease, with lung cancer accounting for an estimated 21% of these deaths [ 1] . Early detection of lung cancer has been shown to reduce mortality by 20%[2] . However, the recommended screening for lung cancer, low dose computed tomography [3], is restricted to high-risk individuals, with an estimated uptake of only 17.54% even within this group due to financial and other barriers [4] . Clearly, there is a need for more accessib","cbCaioeubCjnSKSm","https://ap.wps.com/l/cbCaioeubCjnSKSm","pdf",2609199,17,"English","# Abstract\n# Introduction\n## Need for more accessible screening\n## Clonal hematopoiesis and immune-cell mutations\n## Development of the blood-based screening approach","[{\"question\":\"What is the main goal of the proposed approach?\",\"answer\":\"To develop a blood-based lung cancer screening panel using clonal hematopoietic mutations as predictive biomarkers.\"},{\"question\":\"How were the predictive mutations selected?\",\"answer\":\"Ninety-eight potentially pathogenic clonal hematopoietic mutations were identified using sequencing data from lung cancer samples.\"},{\"question\":\"How well did the logistic regression model perform?\",\"answer\":\"It classified lung cancer and non-cancer blood samples with 94.12% sensitivity and 85.96% specificity across multiple cohorts.\"}]","An approach for developing a blood-based screening panel for lung cancer based on clonal hematopoietic mutations - research article | PDF",1790043223,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f94d0c12ba47d364c637a7535816d421.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56cc6f9c851b21f65e109c9fdeada12d.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00924f983d9354216b95836d6dfb36f7.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b4e07561bc39566513b9d5300a54571.webp",980,1268]